25.05.15 (¸ñ) 22:31

Dailypharm

  • Çà»ç & µ¿Á¤
    • µ¥Àϸ®ÆÊ-KRPIA,±¹Á¦ ½ÉÆ÷Áö¾ö
      µ¥Àϸ®ÆÊ°ú KRPIA´Â ¿À´Ã(23ÀÏ) ¡®±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼­ Çѱ¹ÀÇ ¿ªÇÒ¡¯À» ÁÖÁ¦·Î ±¹Á¦½ÉÆ÷Áö¾öÀ» °³ÃÖÇÑ´Ù. ±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼­ 1)IND ½ÂÀοä°Ç ¹× ÀýÂ÷ÀÇ ÇöÀç ¹× Á¦¾ð 2)°¡±³ÀÚ·áÀÇ ¿ä°Ç ¹× ¿î¿µ, ±×¸®°í Á¦¾ð¿¡ ´ëÇØ °¢±¹ÀÇ ¿¬ÀÚµéÀÌ ¹ßÇ¥ÇÏ°í ³íÀÇÇϱâ À§ÇÑ ±¹Á¦±Ô¸ðÀÇ ½ÉÆ÷Áö¾ö.
      *ÁÖÁ¦ : ±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼­ Çѱ¹ÀÇ ¿ªÇÒ(Role of Korea in Global Drug Development Symposium)
      *ÀϽà : 2007³â 11¿ù 23ÀÏ ¿ÀÀü 8½Ã30ºÐ~¿ÀÈÄ 5½Ã
      *Àå¼Ò : ½ºÀ§½º±×·£µåÈúưȣÅÚ (È«Àºµ¿) ±×·£µåº¼·ë
      *ÁÖÃÖ : KRPIA Çã°¡µî·ÏÀ§¿øÈ¸
      *ÁÖ°ü : µ¥Àϸ®ÆÊ
      *ÈÄ¿ø : ½ÄǰÀǾàǰ¾ÈÀüû
      *ŸÀÓ½ºÄÉÁì(¿¬Á¦ ¹× ¿¬»ç)
      -08:30-09:00 : Registration µî·Ï
      -09:00-09:20 : Opening °³È¸»ç(KFDA/KRPIA Chair
      -09:20-09:50 : IND management in Korea = Çѱ¹ÀÇ ÀÓ»ó½ÃÇè°èȹ ½ÂÀÎ °ü¸®ÇöȲ(KFDA, ÁÖ±¤¼ö ÆÀÀå)
      -09:50-10:30 : Global drug development: what role will Korea and other Asia countries play in the future? (including future suggestion on bridging data in Korea) = ±Û·Î¹ú ÀǾàǰ°³¹ß¿¡¼­ ÇâÈÄ Çѱ¹°ú ´Ù¸¥ ¾Æ½Ã¾Æ ±¹°¡ÀÇ ¿ªÇÒ - ÇâÈÄ Çѱ¹¿¡¼­ °¡±³ÀÚ·á¿¡ ´ëÇÑ Á¦¾ð(TBD)
      -10:30~11:10 : Overview regulatory procedures for clinical trial applications in Europe including the comparison of data requirements of EU, US and Korea especially in early phases = À¯·´¿¡¼­ ÀÓ»ó½ÃÇè½ÅûÀ» À§ÇÑ ±ÔÁ¦°úÁ¤ÀÇ ÀÌÇØ¿Í Ãʱ⠴ܰè ÀÓ»ó½ÃÇèÀ» À§ÇÑ °úÁ¤¿¡ ´ëÇÑ À¯·´, ¹Ì±¹ ¹× Çѱ¹Á¦µµÀÇ ºñ±³(GSK, Ismet Samji)
      -11:10-11:30 : Coffee Break
      -11:10-11:40 : KFDA experience and improvement in clinical trial application review = ÀÓ»ó½ÃÇè°èȹÀÇ ½É»ç°úÁ¤¿¡¼­ ¾òÀº KFDAÀÇ °æÇè°ú °³¼±Á¡(KFDA, ¹Úâ¿ø¿¬±¸°ü)
      -11:40-12:00 : Industrial learning and suggestion on IND requirements and procedures in Korea = ÀÓ»ó½ÃÇè½ÂÀÎ ½Åû°úÁ¤¿¡¼­ ¾ò¾îÁø ±¹³» Á¦¾à»ê¾÷ÀÇ °æÇè ¹× Á¦¾ð(GSK, À̼ÒÁ¤ ÆÀÀå)
      -12:00-13:00 : Lunch
      -13:00-13:40 : Accelerated Clinical Development Program through Adaptive Clinical Trial Design = »õ·Î¿î ÀÓ»ó½ÃÇè µðÀÚÀÎ(Adaptive Clinical Trial Design)À» ÅëÇÑ Àӻ󰳹߰úÁ¤ÀÇ °¡¼ÓÈ­(BMS, Amit Roy)
      -13:40-14:10 : CDE¡¯s perspective in bridging data requirements and procedures in Taiwan = ÀǾàǰ ½ÃÆÇ½ÂÀÎÀ» À§ÇÑ ´ë¸¸¿¡¼­ °¡±³ÀÚ·á¿¡ ´ëÇÑ ¿ä°Ç ¹× ÀÌ¿¡ ´ëÇÑ ´ë¸¸ CDEÀÇ ¿î¿µ ¹× ÇâÈÄ Àü¸Á(CDE, Wen-Hsin Chiu)
      -14:10-14:40 : PMDA¡¯s perspective in bridging data requirements and procedures in Japan = ÀǾàǰ ½ÃÆÇ½ÂÀÎÀ» À§ÇÑ ÀϺ»¿¡¼­ °¡±³ÀÚ·á¿¡ ´ëÇÑ ¿ä°Ç ¹× ÀÌ¿¡ ´ëÇÑ ÀϺ» PMDAÀÇ ¿î¿µ ¹× ÇâÈÄ Àü¸Á(PMDA, UYAMA YASHIASKI)
      -14:40-15:10 : Coffee Break
      -15:10-15:40 : KFDA experience and future prospect in bridging data review = °¡±³ÀÚ·á ½É»ç°úÁ¤¿¡¼­ ¾òÀº KFDA °æÇè ¹× ÇâÈÄ Àü¸Á(KFDA, ¹ÚÀμ÷¿¬±¸°ü)
      -15:40-16:10 : lndustrial learning and suggestion on bridging data requirements and procedures in Korea = °¡±³ÀÚ·á Áغñ°úÁ¤¿¡¼­ ¾ò¾îÁø ±¹³»Á¦¾à»ê¾÷ÀÇ °æÇè ¹× Á¦¾ð(Pfize, ±èÈñ¼± ºÎÀå)
      -16:10-17:00 : Panel Discussion - Simultaneous Global Drug Development = ±¹Á¦Àû ÀǾàǰµ¿½Ã°³¹ß °úÁ¤¿¡¼­ Çѱ¹ÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÆÐ³ÎÅäÀÇ(ÁÂÀå, »ç³ëÇÇ ¾Æº¥Æ¼½º µµ¿ø »ó¹«)
      ÀԷ½ð£ : 2007-11-21 09:34:56
ÀÎÅͳݽŹ®µî·Ï¹øÈ£: ¼­¿ï,¾Æ52715 | µî·ÏÀÏÀÚ 2019.11.20 | ¹ßÇàÀÏÀÚ 2019.11.20 | ¹ßÇàÀÎ : ÀÌÁ¤¼® | ÆíÁýÀÎ : °¡ÀÎÈ£
¹ßÇàÁÖ¼Ò: ¼­¿ï½Ã ¼ÛÆÄ±¸ ¹ý¿ø·Î 128 ¹®Á¤ SK V1 GL ¸ÞÆ®·Î½ÃƼ Aµ¿ 401È£
ÀüÈ­ : 02-3473-0833 |ÆÑ½º : 02-3474-0169 | û¼Ò³âº¸È£Á¤Ã¥(Ã¥ÀÓÀÚ °­½Å±¹)
Contact dailypharm@dailypharm.com for more information
µ¥Àϸ®ÆÊÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)¸¦ ¹«´Ü »ç¿ëÇÏ´Â °ÍÀº ÀúÀ۱ǹý¿¡ ÀúÃ˵Ǹç, ¹ýÀû Á¦À縦 ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.